Stockreport

Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth

Heron Therapeutics, Inc.  (HRTX) 
Last heron therapeutics, inc. earnings: 3/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: herontherapeutics.gcs-web.com/investor-home
PDF CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today annou [Read more]